Q-omics provides the consensus-scored MIR4300HG profile across patient tissues and cancer cell-line models. MIR4300HG expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR4300HG is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR4300HG RNA expression shows 6,757 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where MIR4300HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4300HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4300HG survival associations across molecular data types. MIR4300HG RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4300HG RNA expression–survival associations across cancer types. High MIR4300HG expression shows unfavorable associations in KICH, COAD, KIRC and BLCA, but favorable associations in LGG and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR4300HG RNA expression.
This table summarizes MIR4300HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4300HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4300HG shows lower tumor expression in THCA and higher tumor expression in BRCA, LUSC and HNSC. The BRCA box plot shows higher MIR4300HG RNA expression in tumor versus normal tissue (log2 FC = +0.124, t-test p < 0.001).
This table shows molecular features associated with MIR4300HG in patient tissues and cancer cell lines. In patient samples, MIR4300HG shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
